Deck Bio Heads to San Diego to Showcase Solid Tumor Therapy Platform

The company’s leadership will use the back-to-back conferences to detail their proprietary approach, which utilizes a single engineered TCR-based binder to recognize multiple cancer-associated peptide-major histocompatibility complexes. CEO Jack Silberstein emphasized that while T cell engagers have historically dominated hematologic malignancy treatments, the shift toward solid tumors necessitates a more nuanced design to overcome existing biological hurdles. By targeting independent pMHCs simultaneously, the firm aims to broaden patient eligibility and enhance the durability of therapeutic responses.

Deck Bio’s schedule includes a technical workshop on June 23 regarding global regulatory modeling and a scientific presentation on June 24 at the Westin San Diego Bayview. Concurrently, the team will participate in the BIO International Convention’s Start-Up Stadium and a panel discussion on oncology therapeutic modalities. These sessions will provide a public look at the company’s internal toolkit, which integrates their dbTv receptor stabilization, dbTCE formatting, and dbSCOPE specificity profiling technologies as they move DBXO-1 through preclinical development.